Sign in Subscribe
Nervous system diseases

Klotho Neurosciences Expands into Longevity Focus with Complementary Technologies Acquisition

Strategic Insights

— 1 min read

Klotho Neurosciences, Inc., a NASDAQ-listed company, is evaluating the acquisition of technologies aimed at supporting healthy brain function, organ health, and longevity. Building on its core programs targeting brain aging and neurodegenerative diseases, the company is now exploring adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases, promoting a longer, healthier life.

Key Takeaways:

  • Klotho Neurosciences is evaluating the acquisition of complementary technologies to support healthy brain function, organ health, and longevity.
  • The company aims to expand its proprietary anti-aging Klotho platform to slow biological aging and reduce the burden of age-related diseases.
  • The human Klotho gene is strongly linked to aging and longevity, with levels declining with age and contributing to age-related disorders.
  • Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.
  • The Klotho gene has pleotropic actions modulating critical cellular pathways, including insulin resistance, insulin-like growth factor-1, and Wnt signaling pathways.
  • The company is assembling a team to evaluate genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin, and their isoforms.
  • Dr. Joseph Sinkule, CEO of Klotho Neurosciences, stated that the company's mission is to identify and develop complementary assets to delay age-related outcomes through targeted research and intervention.
  • Shalom Hirschman, M.D., a world-renowned physician and senior consultant to the Company, emphasized the importance of the Klotho gene as a master gene with pleotropic actions.

Statistics:

  • Klotho levels decline with age, contributing to age-related disorders.
  • Silencing of the Klotho gene accelerates multi-organ deterioration.
  • The Klotho gene modulates critical cellular pathways, including insulin resistance and Wnt signaling pathways.

Sources:

  • Klotho Neurosciences, Inc. press release dated [insert date or remove if not available]
  • Klotho Neurosciences, Inc. (NASDAQ: KLTO)
  • Dr. Joseph Sinkule, CEO of Klotho Neurosciences
  • Shalom Hirschman, M.D., senior consultant to Klotho Neurosciences

Read more